Sign in

You're signed outSign in or to get full access.

Jeffrey Kraws

Jeffrey Kraws

Research Analyst at Crystal Research Associates

New York, NY, US

Jeffrey Kraws is the CEO and Senior Research Analyst at Crystal Research Associates, specializing in healthcare and pharmaceutical equity research, with a deep focus on biotechnology and life sciences companies. Over a career spanning more than 36 years, he has covered a diverse array of innovative small- and mid-cap companies and is recognized for his successful articulation of their stories to Wall Street, though specific performance metrics and company names are not publicly listed. Kraws began his financial career after earning an MBA from Cornell University, holding senior positions at Ryan Beck, Gruntal & Co., First Union Securities, Nationsbanc Montgomery, BT Alex Brown, and ABB Aros Securities before co-founding Crystal Research Associates in 2003. He is well-known for industry recognitions and awards, bolstered by his academic and professional credentials, including significant experience in investor relations and competitive analysis at Bristol-Myers Squibb.

Jeffrey Kraws's questions to GeoVax Labs (GOVX) leadership

Question · Q1 2025

Asked about the safety profile of the Mpox vaccine, specifically regarding potential complications like myocarditis, and also inquired about government support for GeoVax's plans to establish U.S.-based MVA vaccine manufacturing.

Answer

The executive affirmed the MVA vector's excellent safety profile, noting it was developed for immunocompromised individuals and does not replicate in humans, hence no such side effects have been observed. Regarding manufacturing, he confirmed the current need to work with partners abroad but mentioned their proposal for an advanced, U.S.-based MVA manufacturing process was deemed appropriate for funding by BARDA and is under consideration as funds become available. They are actively lobbying legislators for support.

Ask follow-up questions

Fintool

Fintool can predict GeoVax Labs logo GOVX's earnings beat/miss a week before the call

Question · Q3 2024

Asked about the effort to include immunocompromised patients, the duration of studies to prove durability, and the enrollment timeline for the 10,000-patient trial.

Answer

The immunocompromised population is a primary focus. They aim to show durability over at least one year, though it's challenging to measure. The 10,000-patient trial is expected to enroll fully within 6 months of starting.

Ask follow-up questions

Fintool

Fintool can write a report on GeoVax Labs logo GOVX's next earnings in your company's style and formatting